Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: A systematic literature review and post hoc analysis of the appeal study

Smit, Riekie; Gubanova, Elena; Kaufman, Joely; Landau, Marina; Molina, Beatriz; Andriopoulos, Bill; Maisonobe, Pascal; Prygova, Inna; Redaelli, Alessio

doi:10.1016/j.toxicon.2020.11.489

Cited by 4 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main results of the study, reported by Joseph et al, revealed a tendency toward higher response rates, with subjects achieving ≥2‐grade improvements alongside severity scores of 0 (none) or 1 (mild), and longer duration of aesthetic effect with increasing ABO dosage when assessed over a 9‐month period 21 . Incidence of adverse events was consistently low across all ABO doses and comparable with the literature regarding safety with the licensed dose 3‐13,21 . Here, we report subject self‐assessment of efficacy, as well as satisfaction and FACE‐Q data from the same ABO dose‐ranging study with the aim of advancing understanding regarding the relationship between treatment efficacy, satisfaction, and psychological well‐being with escalating ABO dose 21 .…”

Section: Introductionsupporting

confidence: 77%

“…The current analysis also provides important insights concerning the psychological benefits that may accompany high levels of satisfaction with successful aesthetic treatments. Satisfaction has become an important indicator of treatment success and is rapidly becoming a standard parameter reported in studies designed to examine the efficacy of aesthetic treatments, such as ABO 2,5‐7,10,12‐17,24 2,5‐7,10,12‐17,24 …”

Section: Discussionmentioning

confidence: 99%

“…Satisfaction has become an important indicator of treatment success and is rapidly becoming a standard parameter reported in studies designed to examine the efficacy of aesthetic treatments, such as ABO 2,5‐7,10,12‐17,24 2,5‐7,10,12‐17,24 …”

Section: Discussionmentioning

confidence: 99%

“…Specialist tools, such as the FACE‐Q™ instrument, provide a standardized model to capture satisfaction with appearance and health‐related QoL following aesthetic procedures 17‐19 . Over recent years, subject satisfaction and psychological well‐being parameters have been increasingly incorporated within randomized and observational studies examining the aesthetic efficacy of botulinum toxin type A treatments for facial lines, reflecting the impact of such treatments on QoL and their importance as a measure of effectiveness 2,5‐7,10,12‐17 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines

Dayan

Joseph²,

Moradi³

et al. 2022

J of Cosmetic Dermatology

Self Cite

View full text Add to dashboard Cite

Background Previous studies indicate that the efficacy and durability of a single AbobotulinumtoxinA (ABO) treatment for moderate to severe glabellar lines may be enhanced with increasing dose, while safety outcomes remain consistent with those of the licensed dose (50 U). Aims Evaluation of subject‐reported indicators of treatment efficacy, satisfaction, and psychological well‐being with ABO dose escalation. Methods A Phase 2, 36‐week, multicenter, randomized, dose‐ranging, double‐blind, placebo‐controlled study was conducted in adults with moderate to severe glabellar lines. Subjects received a single ABO treatment, dosed at 50, 75, 100, or 125 U, or placebo. Efficacy endpoints comprised subject‐assessed improvement in line severity of ≥1‐grade from baseline at maximum frown, global aesthetic improvement scale (GAIS) grade, FACE‐Q™ appraisal of lines, psychological well‐being and age, and subject satisfaction. Results The study included 399 subjects (88.2% were female). Respective responder rates (≥1‐grade improvement) with ABO 50–125 U doses ranged between 96.3%–100% at Week 4, 65.0%–67.9% at Week 24, and 33.8%–44.4% at Week 36. GAIS responder rate and FACE‐Q appraisal of lines showed a similar pattern of change. Satisfaction was high and psychological well‐being was improved from Week 4 through Week 36, with natural, youthful, and refreshed appearance reported for all ABO doses. Conclusions A single ABO treatment (dosed at 50–125 U) provided significant and sustained improvements in glabellar line severity over durations up to 36 weeks, versus placebo. Treatment satisfaction was high with all doses. Participants reported natural and youthful appearance, alongside improvements in psychological well‐being.

show abstract

Section: Introductionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines

Dayan

Joseph²,

Moradi³

et al. 2022

J of Cosmetic Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 ABO treatment satisfaction remained high through week 36 (approximately 9 months); beyond previously reported expectations for a single treatment (≤6 months post-injection). 23 The ability to extend treatment efficacy without impacting safety could influence the frequency of repeat treatments required over time.…”

Section: Discussionmentioning

confidence: 99%

AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study

Joseph¹,

Moradi²,

Lorenc³

et al. 2021

JDD

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of AbobotulinumtoxinA (ABO) dose escalation in the correction of moderate-to-severe glabellar lines. Design: Phase 2, 36-week, multicenter, randomized, dose-ranging, double-blind, placebo-controlled study. Methods: Adults with moderate-to-severe glabellar lines received a single ABO treatment, dosed at 50, 75, 100, or 125 U, or placebo. Primary endpoint was week 4 composite ≥2-grade responder rate among those achieving a severity score of 0 (none) or 1 (mild) at maximum frown, evaluated using concurrent investigator and subject assessments. Secondary endpoints included ≥1-grade severity improvement, duration of effect, and reporting of treatment-emergent adverse events (TEAEs). Results: Overall, 399 subjects were included (88.2% were female). Week 4 composite ≥2-grade ABO responder rate was 80.0% (50 U), 88.8% (75 U), 90.0% (100 U) and 95.1% (125 U), versus 2.6% with placebo (P<0.001). Responder rate (≥1-grade) ranged between 53% (50 U) and 69% (125 U) at week 24 and between 18% (50 U) and 31% (125 U) at week 36. Median time (weeks) to return to baseline severity/worse, among those scoring 0 (none) or 1 (mild), was 32.3 (50 U), 34.3 (75 U), 36.0 (100 U) and 36.6 (125 U), versus 23.7 (placebo). ABO-related TEAEs were reported in 4% of subjects (80% were mild). No seroconversion to ABO neutralizing antibodies was seen. Conclusion:A single ABO treatment provided rapid and effective improvements in glabellar line severity at all doses. Higher doses tended to demonstrate elevated response rates and longer duration of effect. All ABO doses were well-tolerated with low TEAE incidence.

show abstract

Is the duration and effectiveness of cosmetic effects from botulinum toxin decreasing? results from a survey of 400 healthcare professionals

Sergio O,

L ST,

María José

et al. 2024

JDC

View full text Add to dashboard Cite

Botulinum toxin is the leading cosmetic procedure in aesthetic medicine.Its duration and magnitude of effects has been proved through time. Nevertheless, in the last two years, non-scientific reports suggested that the duration and the effectiveness of botulinum toxin A (BoNTA) treatment outcomes may be decreasing, regardless BoNTA type. In our paper, we describe the results of a survey of more than 400 healthcare professionals, mostly from Latin America, about the duration of the effects and the effectiveness of treatment with BoNTA in the last two years.

show abstract

Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: A systematic literature review and post hoc analysis of the appeal study

Cited by 4 publications

References 0 publications

Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines

Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines

AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study

Is the duration and effectiveness of cosmetic effects from botulinum toxin decreasing? results from a survey of 400 healthcare professionals

Contact Info

Product

Resources

About